Pharmaceutical

COPD market to expand with AstraZeneca’s focus on biologics and strong portfolio growth

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.

Jan 18, 2025 - 06:00
COPD market to expand with AstraZeneca’s focus on biologics and strong portfolio growth
The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.
Read the original article

Tags:

Previous Article

FDA beats EMA to most approved new drugs in 2024

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA calls for treatments for meth and cocaine addiction

FDA calls for treatments for meth and cocaine addiction

Oct 4, 2023

EC grants approval to Merck’s Keytruda for gastric cancer

EC grants approval to Merck’s Keytruda for gastric cancer

Aug 30, 2023

FDA will not meet ahead of bluebird bio’s sickle cell disease gene therapy PDUFA date

FDA will not meet ahead of bluebird bio’s sickle cell d...

Aug 16, 2023